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ABSTRACT 
The 5-HT7 receptor is the most recent addition to the 5-HT receptor family and has been 
linked to a variety of physiological and pathophysiological processes. Well established antide-
pressant pharmaceuticals have recently been found to activate the 5-HT7 receptor, supporting 
the role of the 5-HT7 receptor in the antidepressant mechanism. The synthesis of potent selec-
tive 5-HT7 receptor antagonists could afford a greater understanding of the 5-HT7 receptor 
function as well as lead to potential drug candidates. 
The synthesis of unfused biheteroaryl derivatives as 5-HT7 receptor ligands has been de-
scribed within. These compounds have been tested for biological activity on the 5-HT6 and 5-
HT7 receptors. 4-(3’-Furyl)-2-(N-substituted-piperazino)pyrimidines were found to be potent 5-
HT7 receptor ligands. 4-(2’-Furyl)-2-(N-substituted-piperazino)pyrimidines have shown high se-
lectivity for the 5-HT7 receptor over the 5-HT6 receptor. 
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1 INTRODUCTION (LITERATURE REVIEW) 
Serotonin (5-hydroxytryptamine, 5-HT) is a neurotransmitter responsible for a variety of 
biological functions in animals.1 In humans, the effects of 5-HT are achieved through interac-
tions with seven different serotonin receptor families, 5-HT1-7.
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Figure 1. 5-Hydroxytryptamine (5-HT, Serotonin) 
In the central nervous system (CNS), many processes are directed by serotonin such as 
feeding, mood, cognition and memory.1,2 In the peripheral nervous system (PNS), serotonin re-
gulates cardiovascular and gastrointestinal functioning, smooth muscle contractions, and plate-
let aggregation.1,2 Given the many processes governed by serotonin, 5-HT receptors have prov-
en to be successful medicinal targets for the treatment of many physiological disorders.2,6 Many 
current therapeutic agents disrupt or modulate activity of 5-HT receptors through various 
chemical interactions.2 Each of the seven 5-HT receptor families fills a specific role in achieving 
the physiological and pathophysiological functions regulated by serotonin.2,6 Synthesis of a 5-HT 
ligand with receptor family selectivity could afford more specific and efficient treatment and 
consequently minimize drug side effects.  
Pursuit of a potent ligand that expresses selectivity for a specific 5-HT receptor family 
would not be modeled after 5-HT because the native ligand 5-HT is inherently non-selective. 
The molecule must maintain the 5-HT receptor binding pocket specifications but must be chem-
2 
ically distinct to avoid unwanted biological interactions. The 5-HT7 receptor is the most recently 
discovered 5-HT receptor and it has generated the interest of medicinal chemists as a potential 
therapeutic target for the treatment of clinical depression.6 The development of more potent 
and selective 5-HT7 receptor ligands is driven by the potential for the future medicinal applica-
tions. 
1.1 Discovery of Serotonin 
5-HT was discovered independently by two American research groups. In the early 
1930’s Erspamer was investigating the chemical responsible for smooth muscle tissue contrac-
tions in rats.3 Erspamer’s investigation led to the successful isolation of 5-HT from the enteroch-
romaffin cells in the gut from which he named it enteramine.3 Erspamer researched the role of 
5-HT on smooth muscle contractions for many years and published volumes of literature under 
the enteramine title.3 Aside from being produced in large quantities the enterochromaffin cells 
in the gut by, 5-HT is stored in considerable quantities on blood platelets to aid in aggrega-
tion.1,2 In 1948, 5-HT was isolated from blood serum by a research group consisting of Page, 
Rapport, and Green.1,3 Their search for a chemical component in blood responsible for hyper-
tension would eventually lead to the isolation of 5-HT. The name serotonin was born from the 
marriage of the two ideas that 5-HT was isolated from blood serum (“ser”) and increases tone 
(“tonin”) or constriction in blood vessels.1, 3 Soon it was revealed that enteramine and serotonin 
were actually the same substance.1,3 The consolidation of enteramine and serotonin literature 
combined with the commercial synthesis of 5-HT in 1952 afforded a surge in 5-HT investiga-
tion.1,3   
3 
In 1953, Twarog, a Harvard PhD candidate at the time, published an important discovery 
under the advisement of Page, co-discoverer of serotonin.4 Twarog had produced a sensitive 
bioassay to quantitatively detect serotonin in mammalian tissues using mollusk heart.4 Mam-
malian tissues were pulverized and organic tissue extracts were then tested on Twarog’s sero-
tonin bioassay. Her bioassay detected 5-HT in many tissues, but most importantly the concen-
tration of 5-HT throughout brain tissue.4 Twarog’s findings opened the door for investigators to 
probe the role of serotonin in the brain. Research would soon be jump started by an important 
observation of the structural similarities between 5-HT and a well known psychotropic drug. 
 Woolley and Shaw were one of the first research groups to realize the connection be-
tween the powerful mind altering substance lysergic acid diethylamide (LSD-25, LSD, Figure 2) 
and 5-HT.5 At this time it was well known that compounds structurally related to naturally oc-
curring hormones cause disturbances to normal biological function of endogenous ligands.5 Af-
ter Hoffman’s total synthesis of LSD-25 in 1938, it was clear that LSD-25 and 5-HT shared struc-
tural similarities. In fact LSD-25 contains 5-HT as a molecular scaffold.5 Woolley and Shaw noted 
that the hallucinogenic affects caused by LSD consumption were strikingly similar to symptoms 
of mental disorders and soon proposed the cause for mental disturbances to be attributed to 
serotonin deficiency.5 Soon after, the discovery that LSD-25 inhibited the function of serotonin 
provided support for their hypothesis. Research concerning serotonin receptors as drug targets 
would soon become a very exciting and intriguing area of investigation.5 
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Figure 2. Lysergic Diethyl Amide (LSD-25, LSD) 
1.2 The 5-HT Receptor 
The 5-HT receptor has been found widely expressed throughout the CNS and PNS with 
receptor functions linked to a variety of physiological processes. 5-HT receptor regulation has 
been linked to developmental, cardiovascular, gastrointestinal, endocrine function, sensory 
perception, aggression, appetite, sleep, sex, mood, and memory.1-2, 6 The 5-HT1-7 receptors be-
long to a family of proteins called G-protein coupled receptors (GPCRs), with the exception of 
the ligand-gated ion channel 5-HT3 receptor.
6 G-protein coupled receptors consist of seven non-
polar alpha helices spanning the cell membrane with an N-terminus extracellular portion in-
volved with ligand binding and an intracellular carboxy-terminus portion involved with signal 
communications within the cell. 6, 28-29 Binding occurs when a ligand docks to the extracellular 
portion of the GCPR, and the ligand is held in place through specific ligand- receptor protein re-
sidue interactions.6 Binding activates a structural change in the receptor protein conformation. 
This structural change generates a cascade of intracellular events that will ultimately communi-
cate the extracellular transmission and result in the appropriate biological response.6, 28-29  
Activation of a 5-HT receptor begins with the docking of a molecule to the extracellular 
binding pocket of the receptor protein. A molecule with affinity towards binding to the receptor 
active site is called a receptor ligand. Different ligands can activate a receptor and achieve vari-
5 
ous responses, which results in the distinction between receptor agonists, antagonists, and in-
verse agonists.6 The term receptor agonist refers to a molecule that has affinity for binding to a 
receptor and upon docking the ligand mimics the effect of the native ligand, in other words in-
creasing the signal for serotonin function expression. A receptor antagonist, however, refers to 
a molecule that binds in the receptor active site and inhibits agonist docking and thereby block-
ing the expression of the native ligand function. There is a third type of receptor ligand which is 
called an inverse-agonist. An inverse agonist is a ligand that binds in the receptor active site and 
decreases intracellular signaling, posing the negative effect of a receptor agonist.  
The existence of multiple 5-HT receptors has allowed serotonin to achieve such a wide 
variety of physiological control.1-2,6 In fact, there are fourteen different subtypes that have been 
grouped into seven families, 5-HT1-7 respectively. This classification does not include the mul-
tiple receptors arising from alternate gene splicing or the 5-HT receptor mRNA.1-2 The seven 5-
HT receptor families have been extensively investigated for the role each play in the processes 
regulated by serotonin. This has been aided by the advancement in receptor cloning technolo-
gies, gene knock-out mice studies and utilization of potent and selective 5-HT receptor ligands.6-
8 Elucidation of which 5-HT receptor is responsible for specific biological processes would allow 
for future drug design of selective 5-HT receptor ligands as therapeutic agents. 
1.3 Discovery of the 5-HT7 Receptor 
 The 5-HT7 receptor (5-HT7R) was discovered independently by three research laborato-
ries in 1993, making it the most recent addition to the serotonin receptor subtype family and 
bringing the grand total of serotonin receptor subtypes to fourteen.6-8,17 This receptor was dis-
covered by analysis of brain cDNA libraries searching for sequences sharing homology to known 
6 
5-HT receptors.17,22 Studies on the 5-HT7R have relied heavily on the use of selective antagonists 
and 5-HT7R knockout mice.
17, 19 Being the most recently discovered, the 5-HT7 receptor still re-
mains one of the least understood 5-HT receptors. 
 After the discovery of 5-HT7, it became apparent that many previously established 5-HT 
receptor mediated processes may have been interpreted erroneously.6 One such example is the 
role of 8-hydroxy-2( di-n-propylamino)-tetralin (8-OH-DPAT, Figure 3), which was previously 
thought to be a selective agonist for the 5-HT1A receptor, but has since been discovered to po-
tent agonist activity for the 5-HT7 receptor.
2,6  
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Figure 3. 8-hydroxy-2(di-n-propylamino)-tetralin (8-OH-DPAT) 
In fact, many compounds with structural diversity have been shown to possess affinity 
for the 5-HT7 receptor.
2,15 A figure has been compiled below including structural examples of 
non-selective and selective ligands for the 5-HT7 receptor.
15 
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Figure 4. Selective and Non-Selective 5-HT7 Receptor Ligands 
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Figure 4. Examples from the six general classes of 5-HT7 receptor antagonists as outlined by Kolaczkows-
ki et al. and have been numbered according to each class are shown. (1) ergoline derivatives, (2) apor-
phine derivatives, (3) tricyclic psychotropic agent derivatives, (4) arylpiperidine, arylpiperazine deriva-
tives *LCAPs+ and β-carboline derivatives [LCBCs], (5) arylsulfonamidoalkylamine derivatives, (6) com-
pounds reserved for selective antagonists that are structurally more diverse than the previous five 
classes. 
 
In fact, the 5-HT7R antagonists have shown to display a wide variety of structural com-
ponents.15 The above figure has been compiled to visualize six classes of 5-HT7R antagonists 
that have been generalized by Kolaczkowski et al.: (1) nonselective ergolines, (2) nonselective 
8 
aporphines, (3) nonselective tricyclic psychotropic agents, (4) arylpiperidines, arylpiperazines 
*LCAPs+ and β-carbolines [LCBCs], (5) selective arylsulfonamidoalkylamines, (6) and other di-
verse structure selective antagonists such as diaminotriazines.15 
A crystal structure for the 5-HT7R has not been achieved, making binding pocket 3-D 
evaluation to rely heavily on molecular modeling using potent ligand binding information. The 
first pharmacophore model was developed by Lopez-Rodriguez et al in 2000.30 This receptor 
pharmacophore was developed to reveal key structural components for 5-HT7 receptor anta-
gonist binding and employed 30 ligands with structural diversity.30 The molecular modeling cal-
culations predict the minimum structural requirements for binding include an aromatic ring, a 
basic nitrogen atom (positive ionizable center, PI) hydrogen bond acceptor (HBA), and a hydro-
phobic region (HB) 4.9-5.9 Ǻ apart from the basic center.30 An updated pharmacophore model 
was published by Lopez-Rodriguez in 2003 using a series of different ligands making minor 
changes to the structural requirements.31 In 2006, Kolaczkowski et al published a pharmaco-
phore model using selective structurally variant 5-HT7 ligands and reported an interesting dis-
covery.15 It has been reported that there may be more than one binding pocket for the 5-HT7 
receptor, which would account for such structural diversity showing such high affinity.15  
A pharmacophore model recently developed in the Strekowski lab by Jeff Klenc was em-
ployed to design more potent and selective 5-HT7 receptor antagonists.
31 Using available com-
pounds synthesized in the Strekowski lab our pharmacophore model calculations agree with 
the literature Lopez-Rodriguez pharmacophore model.30-31  
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Figure 5. Pharmacophore Model for Selective 5-HT7 Antagonists  
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Figure 5. The pharmacophore model created by Jeff Klenc in the Strekowski laboratory is shown.31 Com-
pound AE-001-39 has been placed side by side with this model to show how this molecule satisfies spa-
tial requirements.  
 
HYD3 is a predicted hydrophobic pocket that exists inside of the 5-HT7 binding pocket 
model. This hydrophobic pocket appears to be less essential for high binding affinity than the 
HBA and PI. In fact, addition of a butyl group to satisfy this 5-HT7 model parameter has shown 
only a slight increase in binding affinity which may be biologically insignificant. In contrast, 5-
HT6 binding affinity increased dramatically for compounds with this hydrophobic addition. A 
more detailed discussion of compound affinity results can be seen later in the Biological Activity 
section. 
10 
1.4 5-HT7 Receptor Function 
In recent studies, evidence reveals that the 5-HT7 receptor might be a novel target for 
medicinal chemists for the treatment of various physiological and pathophysiological disord-
ers.17 The 5-HT7 receptor has suggested involvement in depression,
6 body thermoregulation,9 
circadian rhythm,10 learning and memory,11-12 endocrine and mood regulation,15 and smooth 
muscle relaxation in cerebral arteries.14 These findings indicate that regulation of the 5-HT7 re-
ceptor could be manipulated therapeutically for treatment of such disorders as depression, in-
somnia, and migraines.6,10,14 Considering the many processes that could be controlled by inhi-
biting the 5-HT7 receptor, is a matter of great importance and opportunity to develop more po-
tent selective 5-HT7 receptor antagonists for investigation as potential drug candidates.  
The 5-HT7 receptor distribution throughout the brain has been studied using a combina-
tion of techniques including knock-out mice and radio-labeled 5-HT subtype receptor antagon-
ists.15-16 Localization of the 5-HT7 receptor throughout the brain has stimulated investigation of 
a potential relationship between this receptor and mental illness.16, 20 High concentrations of 
the 5-HT7 receptor were found in the hypothalamus, thalamus, and hippocampus.
16 These find-
ings support 5-HT7 receptor involvement in behavior, cognition, and circadian rhythm regula-
tion.10,16 Depression and schizophrenia are psychiatric disorders that have recently been eva-
luated the 5-HT7 receptor as a target for potential treatment.
20 These two disorders have been 
linked to this receptor using 5-HT7 receptor KO mice and inhibition studies using selective 5-HT7 
antagonists. The results of both studies show comparable therapeutic profiles to known anti-
psychotic and antidepressant drugs currently on the market.18-20  
11 
Currently, there is a need for more potent and selective 5-HT7 receptor antagonists to 
progress investigation concerning the involvement of this receptor and the aforementioned 
mental disorders. These potential therapeutic applications emphasize the importance of future 
investigation and should continue to encourage medicinal chemists to develop more potent 
selective 5-HT7 receptor antagonists. 
2 SYNTHESIS OF UNFUSED BIHETEROARYLS (THIS WORK) 
2.1 Synthesis of Substituted Pyrimidines 
The synthesis of pyrimidines with heteroaryl substituent at position 4 had gone uneva-
luated until the modifications made by Strekowski et al. were published.23 The earliest work 
focused on the addition of lithiated species to the pyrimidine ring, which led to the 1, 6-
dihydropyrimidine intermediate. This intermediate was oxidized back to pyrimidine with the 
use of 2,3-dichloro 5,6-dicyanobenzoquinone (DDQ) (Scheme 1). 
 
Scheme 1. 
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After the lithium addition/substitution reaction was complete, an amine was used to 
displace the chlorine at the 2 position, which led to the desired products in moderate yields 
(Equation 1). 
Cl
NN
N
NN
N
R
HN N R
Toluene
O O
(1)
 
A similar chemistry was used to synthesize the pyrimidine ligands discussed below. 2-
Lithiofuran was generated in THF at low temperature by addition of n-BuLi to furan. After the 
lithiation reaction (Equation 2), the corresponding organolithium reagent was used in situ.  
O
H
O
Li
n-BuLi
THF, -78o
(2)
 
A solution of 2-chloropyrimidine (1) in THF was added to the organolithium reagent at -
78 ˚C (Scheme 2). Once the reaction was complete, the mixture was quenched with water/THF 
(1:1) and the intermediate dihydropyrimidine was rearomatized upon treatment with DDQ to 
give pyrimidine 2. 
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Scheme 2.  
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Compounds 5 and 6 were synthesized by treatment of 2-chloropyrimidine 2 with N- Boc 
protected piperazine yielding 3. Following acidic Boc deprotection the resultant secondary 
amine 4, was treated with the corresponding alkyl halide to produce compounds 5 and 6. Final 
products 5 and 6 were transformed to the hydrobromide salt and fully characterized.  
 
 
HN NH
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OH
O
O
OCH3
9: R =
(3)
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Compounds 7-10 were synthesized using piperazine and the corresponding alkyl halide 
in a ratio of 2:1 to prevent dialkylation (Equation 3). The resulting products 7-10 were used in 
the following reactions without purification (Scheme 3). 
Scheme 3. 
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 Compounds 11-14 were synthesized using substituted piperazines 7-9 in toluene. Excess 
of a piperazine was necessary to achieve higher yield for products 11-14. This direct method 
seen above in Scheme 3 was preferred over the Boc-protected method seen in Scheme 2. This 
preference was determined due to less time spent on purification since compounds 7-9 could 
be used synthetically crude, and for economic factors, as the Boc protecting group added unne-
cessary expense. Final compounds 11-14 were transformed to the hydrobromide salt and fully 
characterized. 
15 
3 BIOLOGICAL ACTIVITY 
Compounds synthesized in the Strekowski laboratory, including compounds prepared as 
part of this work, have been recently evaluated by the National Institute of Mental Health. 
Compounds were selected for binding affinity analysis for the 5-HT6 and 5-HT7 receptors. Ki de-
terminations were generously provided by the National Institute of Mental Health's Psychoac-
tive Drug Screening Program, Contract # HHSN-271-2008-00025-C (NIMH PDSP). The NIMH 
PDSP is directed by Bryan L. Roth MD, PhD at the University of North Carolina at Chapel Hill and 
Project Officer Jamie Driscol at NIMH, Bethesda MD, USA. These binding studies employ a ra-
dio-ligand assay using [H3]LSD at a 1 nM concentration with chlorpromazine as a reference in a 
standard binding buffer following the published procedure.33-34 
3.1 5-HT7 and 5-HT6 Receptor Binding Affinity 
Testing for compounds has been performed at the National Institute of Mental Health 
(NIMH) at the University of North Carolina Chapel Hill. The following table has been populated 
with binding affinity values for the 5-HT6 and 5-HT7 receptor. Abbreviations AE denote com-
pounds of this thesis. Derivatives NF (Nilmi Fernando) and SP (Shirish Paranjpe) are included in 
the following discussion for a comprehensive treatment. 
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Table 1.1: Binding Affinity Results for 4-(2’-Furyl) and 4-(3’-Furyl) pyrimidine derivatives 
Compound ID Structure 5-HT6 Ki (nM) 5-HT7 Ki (nM) 
AE - 001 - 39 N
N
N
O
N
OH
 
N/A* 997.0 
SP - 1 - 65 N
N
N
O
N
OH
2HBr H2O
 
342.0 8.5 
AE - 001 -37 N
N
N
O
N
O
O
2HBr H2O
 
N/A* 58.0 
NTF - 111 - 025 N
N
N
O
N
O
OHBr H2O
 
106.0 0.4 
AE - 001 - 69 N
N
N
O
N
2HBr
 
N/A* 57.0 
NTF - 111 - 065A N
N
N
O
N
2HBr 2H2O
 
70.4 1.6 
*N/A = Less than 50% inhibition in primary assays. Secondary assay not performed.  
 The compounds listed in the table above have been arranged to ease comparison be-
tween the Ki values of three N’-substituted piperazines for both 4-(2’-Furyl) and 4-(3’-Furyl) py-
rimidine derivatives. The N/A* corresponds to primary assay binding affinity below the thre-
shold required by the NIMH to proceed with secondary assay testing. Analysis of the data pre-
17 
sented in this table yields a noteworthy difference between the 5-HT6 receptor binding profile 
for the 2’- and 3’-Furyl isomers. The 2’-Furyl derivatives, AE-001-37, AE-001-39, and AE-001-69, 
lack 5-HT6 affinity. These compounds show high selectivity for the 5-HT7 receptor over the 5-
HT6 receptor.  
The 3’-Furyl isomers, NTF-111-025, SP-1-65, and NTF-111-032, show higher affinity 
(lower Ki values) for the 5-HT7 receptor than the 2’-Furyl isomers. The 3’-Furyl moiety appears 
to increase affinity towards both the 5-HT6 receptor and the 5-HT7 receptor. These results indi-
cate the positioning of the hydrogen bonding acceptor (HBA) plays a critical role in the active 
site for both 5-HT6 and 5-HT7 receptors. The positioning of the HBA is essential for binding to 
the 5-HT6 receptor, as observed by absence of 5-HT6 affinity from the 2’-Furyl pyrimidine deriv-
atives.  Exploitation of the HBA positioning will likely prove an important feature in future syn-
thesis of compounds expressing receptor selectivity.  
Recently in the Strekowski lab, Nilmi Fernando (NTF) and Shirish Paranjpe (SP) have syn-
thesized 2, 4, 6- tri-substituted pyrimidines using the more potent 3’-Furyl derivatives. A table 
has been presented below comparing two N’-substituted piperazines and the Ki values for the 
corresponding di- and tri-substituted pyrimidines. 
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Table 1.2: Binding Affinity Results for Di- and Tri- Substituted Pyrimidines 
Compound ID Structure 4,6 Pyrimidine 
Substituents 
5-HT6 Ki 
(nM) 
5-HT7 Ki 
(nM) 
AE-001-37 N
N
N
O
N
O
O
2HBr H2O
 
2-furyl, H N/A* 58.0 
NTF-111-025 N
N
N
O
N
O
O
HBr 2H2O
 
3-furyl, H 106.0 0.4 
NTF-111-065A 
N
N
N
O
N
O
O
2HBr
C4H9
 
3-furyl, C4H9 72.0 9.0 
AE-001-39 N
N
N
O
N
OH
 
2-furyl, H N/A* 997.0 
SP-1-65 N
N
N
O
N
OH
2HBr H2O
 
3-furyl, H 342.0 8.5 
SP-1 -67 
N
N
N
O
N
OH
2HBr H2O
C4H9
 
3-furyl, C4H9 202.0 7.7 
*N/A = Less than 50% inhibition in primary assays. Secondary assay not performed. 
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Table 1.2 compares 5-HT6 and 5-HT7 Ki values for two N’-substituted piperazines at-
tached to the 2 position on three pyrimidine derivatives. Compounds NTF-111-065A and SP-1-
67 are 4-(3’-Furyl) homologues. The addition of the butyl group to the pyrimidine in SP-1-67 
adds a flexible hydrophobic character to the compound.  
For the two butyl compounds NTF-111-065A and SP-1-67, there is an increase in affinity 
for the 5-HT6 receptor. However, the very potent NTF-111-025 loses 5-HT7R affinity upon addi-
tion of the butyl group as seen in NTF-111-65A, with Ki values of 0.4 and 9.0 respectively. 
For compounds with high affinity for receptor binding, ligand structural geometry must 
conform to the receptor-bound conformation. Using unfused biheteroaryl compounds has al-
lowed for a modeling advantage by restricted conformation possibilities. The use of rigid mole-
cules for receptor modeling allows less room for conformational ambiguity in the natural recep-
tor-bound conformation. The pyrimidine substituted with a furan is limited to two low energy 
conformations referred to as s-cis and s-trans (Figure 6). These low energy conformations occur 
due to maximal electron delocalization at 0o and 180o torsion angles, or s- cis and s- trans re-
spectively. 
Figure 6.  Cis- and trans- 4-(2’-Furyl) and 4-(3’-Furyl)pyrimidine conformations 
N N
O
N N
O
N N
O
N N
O
s- trans s- cis s- trans s-cis
4-(2'-furyl)pyrimidine 4-(3'-furyl)pyrimidine
 
Figure 6. Using the unfused biheteroaryl scaffold of furan and pyrimidine limits the low energy structure 
conformations.   
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The 2’-Furyl substituent on the pyrimidine has been shown to display a preferred low 
energy s-trans conformation.25 Molecular modeling predictions support the 2’-Furyl s-trans con-
formation preference while the 3’-Furyl derivatives possess slight preference for the s-cis con-
formation. Only a slight preference is observed for the 3’-Furyl derivatives as the two confor-
mers are spatially similar. These low energy conformation predictions have been supported ex-
perimentally by NOESY 2-D NMR spectroscopy.25-26  
4 CONCLUSION 
In recent years, the 5-HT7 receptor has attracted the interest of medicinal chemists as a 
therapeutic target for treating many physiological and pathophysiological illnesses. Lacking a 
crystal structure for this receptor, investigators have relied on modern molecular modeling 
techniques and potent receptor ligands to attain some insight into the three-dimensional 5-HT7 
receptor binding pocket. A 5-HT7 pharmacophore model previously developed in the Strekowski 
lab has provided minimum structural requirements for potent ligand binding and has been used 
to develop compounds with high 5-HT7 receptor affinity.  
The development of more potent and selective receptor antagonists will help aid in bet-
ter model calculations and receptor active site understanding. As more selective antagonists 
are discovered, the availability for research into the true 5-HT7R therapeutic potential will be 
expanded accordingly. Biological results from the recently synthesized set of furylpyrimidine 
derivatives show minute structural changes have a profound effect on the affinity for the 5-HT6 
and 5-HT7 receptor. Exploitation of the HBA positioning will play a crucial role in producing 
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more potent and selective 5-HT7 antagonists as well as other structural and functional modifica-
tions to make potent ligands more selective.  
5 EXPERIMENTAL 
5.1 General 
THF was purified by distillation from sodium benzophenone ketyl under a nitrogen at-
mosphere. All reagents were purchased from a commercial source and used as received. 
Glassware was dried in an oven at 120 ˚C, assembled hot and cooled to room temperature un-
der a continuous nitrogen flow prior to use. 1H NMR (400 MHz) and 13C NMR (100 MHz) spectra 
were obtained in CDCl3 at 27 ˚C on a Bruker instrument. Elemental analysis was obtained from 
Atlantic Microlabs, Inc. Melting points are uncorrected. Compound intermediates not sent for 
biological testing have not been fully characterized. Final products were fully characterized by 
1H NMR, 13C NMR, mass spectrometry, and elemental analysis. 
 Radio-ligand binding studies for the 5-HT7 and 5- HT6 receptors were performed accord-
ing to the published procedure by the National Institute of Mental Health.33,34 These binding 
studies employ a radio-ligand assay using tritiated [H3]LSD at a 1 nM concentration and chlor-
promazine as a reference in a standard binding buffer. The “standard binding buffer” was com-
posed of 50 mM Tris HCl, 10 mM MgCl2, and 0.1 mM EDTA at pH 7.4. Cell membrane fractions 
expressing the 5-HT6 and 5-HT7 receptor target were used in the 5-HT6 and 5-HT7 binding stu-
dies respectively. The inhibition constant (IC50) value is estimated from the data which is then 
used to calculate the molecular binding affinity (Ki) using the Cheng-Prusoff equation: 
Ki = IC50/(1 + [ligand]/KD) 
22 
 [Ligand] is the radio-ligand concentration and KD is the radio-ligand affinity constant for 
the target receptor, specifically the 5-HT6 or 5-HT7 receptor.
33,34  Ki is a measure of ligand affini-
ty for a specific receptor. This value is defined as the minimum ligand concentration required 
for binding to half of the receptor protein population without the presence of a radio-labeled 
ligand.33-34  
5.2 Lithium Reagents 
n-Butyllithium (2.5 M in hexanes) was purchased as a commercial reagent. 2-Lithiofuran 
was generated by treatment of furan with n-butyllithium and used immediately27. 
5.3 Synthesis of Pyrimidines 
General procedure for synthesis of 4-(2-furyl)-2-(4-N-substituted-piperazino)pyrimidines 5 
and 6 
Compounds 5 and 6 were prepared as previously described with slight modifications.23-
24 A solution of 2-furyllithium (8.7 mmol) in tetrahydrofuran (THF, 5.0 mL) was treated dropwise 
with 2-chloropyrimidine (1.0 g, 8.7 mmol) in THF (30 mL) at -5 °C under nitrogen atmosphere. 
The mixture was stirred for 30 min at -5 °C and then quenched with water (5.0 mL) in THF (5.0 
mL). After treatment with 2,3-dichloro-5,6-dicyanoquinone (DDQ, 1.9 g, 8.7 mmol), the mixture 
was stirred for 5 min to reach room temperature. The mixture was basified with sodium carbo-
nate (saturated) till pH = 9 and was then extracted with diethyl ether (2 × 30 mL), dried over 
magnesium sulfate, and concentrated in vacuo to provide crude product. The crude product 2 
was purified by chromatography eluting with hexanes/diethyl ether (70:30) to provide 2-
Chloro-4-(2’-furyl)pyrimidine to be utilized in the next step. A solution of compound 2 and N-
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Boc-piperazine in toluene was heated to 80 °C for 48 hours, after which the mixture was cooled 
to room temperature. The reaction mixture was basified with sodium carbonate, extracted with 
Et2O (2 × 20 mL), dried (MgSO4), filtered and concentrated in vacuo. The crude residue was pu-
rified on a chromatotron with EMD 60PF254 silica gel eluting with dichloromethane/methanol 
(100:0 for 100 mL, then 95:5 for 250 mL) to provide 4-(2’-furyl)-2-(N-Boc-piperazino)pyrimidine. 
Subsequent de-protection of the Boc group was accomplished by dissolving 3 in 30% trifluoro-
aceticacid/dichloromethane (3 mL : 7 mL) and stirring the solution under a nitrogen atmos-
phere. The mixture was basified with sodium carbonate, extracted with Et2O (2 × 20 mL), dried 
(MgSO4), filtered and concentrated in vacuo. Complete deprotection was achieved yielding 4 
with minimal impurities allowing for progression to the next synthetic step without further pu-
rification. A solution of compound 4-(2’-furyl)-2-(piperazino)pyrimidine and the corresponding 
alkylhalide in toluene was heated to 80 °C for 72 h, after which the mixture was cooled to room 
temperature. The mixture was basified with sodium carbonate, extracted with EtOAc (2 × 20 
mL), dried (MgSO4), filtered and concentrated in vacuo. The residue was purified on a chroma-
totron with EMD 60PF254 silica gel eluting with dichloromethane/methanol (100:0 for 100 mL, 
then 95:5 for 250 mL) to afford 5 or 6. 
General procedure for synthesis of 4-(2-furyl)-2-(4-N-substituted-piperazino)pyrimidines 11 - 
14 
Compounds 11 – 14 were prepared as previously described with slight modifications.23-24 
A mixture of piperazine (58.1 mmol) and K2CO3 (29.0 mmol) in acetonitrile (30 mL), was added a 
corresponding alkyl halide (29.0 mmol) and heated to reflux overnight. The mixture was al-
lowed to cool to room temperature and then quenched with deionized water and extracted 
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with EtOAc. Organic extracts were combined, dried (MgSO4), filtered and concentrated in va-
cuo. The resulting compounds 7 - 10 were considered to be of satisfactory purity and used in 
the following reactions without further purification. A solution of compound 2 and compounds 
7 - 10 in toluene was heated to 80 °C for 48 hours, after which the mixture was cooled to room 
temperature. The mixture was basified with sodium carbonate, extracted with EtOAc (2 × 20 
mL), dried (MgSO4), filtered and concentrated in vacuo. The residue was purified on a chroma-
totron with EMD 60PF254 silica gel eluting with dichloromethane/methanol (100:0 for 100 mL, 
then 9:1 for 250 mL) to provide compounds 11 - 14.  
5.4 Hydrobromic Salt Preparation 
Formation of the hydrobromide salt was achieved by dissolving compounds 5 - 6, 11, 
and 13 - 14 (0.608 mmol) in MeOH (3 mL) and adding 62% hydrobromic acid (0.608 mmol) 
drop-wise. After five minutes the reaction flask was diluted with Et2O (5 mL) to encourage pre-
cipitation and the resulting solid was filtered and dried in vacuo.  
5.5 Compound Characterization 
2-Chloro-4-(2’-furyl)pyrimidine (2, AE-001-35): This compound was obtained as a white solid in 
72 % yield (556 mg); mp 57 - 59 °C; 1H NMR: δ 8.60 (d, J = 5.2 Hz, 1H), 7.64 (d, J = 2.3 Hz, 1H), 
7.54 (d, J = 5.2 Hz, 1H), 7.40 (d, J = 4.1 Hz, 1H), 6.63 (t, J = 5.2 Hz, 1H); 13C NMR: δ 160.6, 158.7, 
156.9, 149.34, 145.1, 113.4, 112.0, 112.0 
4-(2’-Furyl)-2-(N-Butoxycarbonyl-piperazino)pyrimidine (3, AE-001-64): This compound was 
obtained as a cream colored solid in 69 % yield (750 mg); 1H NMR: δ 8.36 (d, J = 5.1 Hz, 1H), 
7.57 (t, J = .8 Hz, 1H), 7.18 (d, J = 2.8 Hz, 1H), 6.90 (d, J = 5.1 Hz, 1H), 6.56 (d, J = 1.6 Hz, 1H), 3.88 
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(t, J = 4.9 Hz, 4H), 3.54 (t, J = 4.9 Hz, 4H), 1.52 (s, 9H); 13C NMR: δ 160.6, 157.4, 154.9, 153.9, 
151.6, 143.5, 111.2, 110.3, 103.2, 78.9, 42.59, 27.5; 
4-(2’-Furyl)-2-(piperazino)pyrimidine (4, AE-001-67): This compound was obtained as a brown 
oil in 91 % yield (978 mg); 1H NMR: δ 8.34 (d, J = 5.1 Hz, 1H), 7.55 (t, J = .7 Hz, 1H), 7.16 (d, J = 
3.4 Hz, 1H), 6.86 (d, J = 5.1 Hz, 1H), 6.53 (q, J = 2.5 Hz, 1H), 3.85 (t, J = 5.1 Hz, 4H), 2.95 (t, J = 5.1 
Hz, 4H), 1.99 (s, 1H); 13C NMR: δ 160.7, 157.3, 154.9, 151.7, 143.4, 111.1, 110.2, 102.9, 45.1, 
43.9 
4-(2’-Furyl)-2-(4-(3-phenylpropyl)piperazino)pyrimidine (5, AE-001-69): This compound was 
obtained as an amber oil in 62 % yield (88 mg); 1H NMR: δ 8.36 (d, J = 5.1 Hz, 1H), 7.56 (t, J = 1.5 
Hz, 1H), 7.34-7.3 (m, 2H), 7.24-7.22 (m, 3H), 7.20-7.18 (m, 1H), 6.88 (d, J = 5.0 Hz, 1H), 6.54 (q, J 
= 5.1 Hz, 1H), 3.93 (t, J = 4.9 Hz, 4H), 2.69 (q, J = 12.1 Hz, 2H), 2.53 (t, J = 4.9 Hz, 4H), 2.43 (q, J = 
11.7 Hz, 2H), 1.91 (m, 2H); 13C NMR: δ 160.7, 157.3, 154.9, 151.8, 143.4, 141.1, 127.5, 127.4, 
124.8, 111.1, 110.2, 102.9, 57.1, 52.2, 42.8, 32.7, 27.6; Highresolution MS (ESI, positive ion 
mode): calcd. for C21H25N4O (M + 1)
+, m/z 349.2028, found m/z 349.2039. A hydrobromide salt, 
mp > 250 °C. Anal Calcd. for C21H24N4O•2HBr: C, 49.43; H, 5.14; N, 10.98. Found: C, 49.51; H, 
5.36; N, 10.66. 
4-(2’-Furyl)-2-(4-propylpiperazino)pyrimidine (6, AE-001-68): This compound was obtained as 
a amber oil in 54 % yield (45 mg); 1H NMR: δ 8.36 (d, J = 5.1 Hz, 1H), 7.56 (q, J = 1.3 Hz, 1H), 7.17 
(q, J = 2.1 Hz, 1H), 6.87 (d, J = 5.1 Hz, 1H), 6.55 (q, J = 2.6 Hz, 1H), 3.91 (t, J = 5.1 Hz, 4H), 2.54 (t, 
J = 5.1 Hz, 4H), 2.37 (m, 2H), 1.59 (m, 2H), 0.95 (t, J = 7.4 Hz, 3H); 13C NMR: δ 160.6, 157.3, 
154.9, 151.7, 143.4, 111.1, 110.2, 102.9, 59.9, 52.2, 42.7, 19.0, 11.0. A hydrobromide salt, mp > 
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250 °C. Anal Calcd. for C15H20N4O•2HBr: C, 42.78; H, 5.18; N, 12.55. Found: C, 41.50; H, 5.11; N, 
12.90. 
4-(2’-Furyl)-2-(4-ethylhexanoatepiperazino)pyrimidine (11, AE-001-37): This compound was 
obtained as a brown oil in 58 % yield (98 mg); 1H NMR: δ 8.33 (d, J = 5.1 Hz, 1H), 7.54 (d, J = 2.4 
Hz, 1H), 7.15 (d, J = 4.1 Hz, 1H), 6.84 (d, J = 5.1 Hz, 1H), 6.52 (t, J = 5.2 Hz, 1H), 4.13 (q, J = 10.7 
Hz, 2H), 3.89 (t, J = 4.9 Hz, 4H), 2.52 (t, J = 4.9 Hz, 4H), 2.39 (t, J = 7.7 Hz, 2H), 2.31 (t, J = 7.5 Hz, 
2H), 1.65 (m, 2H), 1.57 (m, 2H) 1.36 (m, 2H), 1.26 (t, J = 7.1 Hz, 4H); 13C NMR: δ 172.7, 160.6, 
157.3, 154.9, 151.7, 143.4, 111.1, 110.2, 102.9, 59.2, 57.6, 52.2, 42.6, 33.3, 26.1, 25.5, 23.9, 
13.3; Highresolution MS (ESI, positive ion mode): calcd. for C20H29N4O3 (M + 1)
+, m/z 373.2240, 
found m/z 273.2224. A hydrobromide salt, mp > 250 °C; Anal Calcd. for C20H28N4O3•2HBr•H2O: 
C, 43.49; H, 5.84; N, 10.14. Found: C, 43.68; H, 5.84; N, 10.14. 
4-(2’-furyl)-2-(4-ethylhydroxypiperazino)pyrimidine (12, AE-001-39): This compound was ob-
tained as a pale yellow solid in 86 % yield (240 mg); mp 109-111; 1H NMR: δ 8.34 (d, J = 5.1 Hz, 
1H), 7.56 (d, J = 0.8 Hz, 1H), 7.17 (d, J = 3.4 Hz, 1H), 6.87 (d, J = 5.1 Hz, 1H), 6.53–6.54 (m, 1H), 
3.91 (t, J = 4.9 Hz, 4H), 3.69 (t, J = 5.3 Hz, 2H), 2.87 (s, 1H), 2.59-2.62 (m, 4H); 13C NMR: δ 160.6, 
157.3, 154.9, 151.7, 143.4, 111.1, 110.3, 103.0, 58.6, 56.8, 51.9, 42.7; Highresolution MS (ESI, 
positive ion mode): calcd. for C15H20N4O (M + 1)
+, m/z 275.1508, found m/z 275.1497.; Anal 
Calcd. for C14H18N4O2: C, 61.30; H, 6.61; N, 20.42. Found: C, 61.36; H, 6.78; N, 20.42.  
4-(2’-furyl)-2-(4-hexylpiperazino)pyrimidine (13, AE-001-77): This compound was obtained as a 
yellow oil in 58 % yield (150 mg); 1H NMR: δ 8.32 (d, J = 4.8 Hz, 1H), 7.53 (t, J = 0.8 Hz, 1H), 7.15 
(d, J = 3.4 Hz, 1H), 6.83 (d, J = 5.1 Hz, 1H), 6.51 (q, J = 2.6 Hz, 1H), 3.89 (t, J = 5.1 Hz, 4H), 2.50 (t, 
J = 5.1 Hz, 4H), 2.36 (t, J = 7.8 Hz, 2H), 1.3 (m, 6H), 0.9 (q, J = 6.8 Hz, 3H); 13C NMR: δ 160.6, 
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157.3, 154.8, 151.8, 143.3, 111.0, 110.1, 102.8, 58.0, 52.2, 42.7, 30.8, 26.3, 25.9, 21.6, 13.1; 
Highresolution MS (ESI, positive ion mode): calcd. for C18H27N4O (M + 1)
+, m/z 315.2170, found 
m/z 315.2185. A hydrobromide salt, mp > 250 °C. Anal Calcd. for C18H26N4O•2HBr•1.5H2O: C, 
42.96; H, 6.21; N, 11.13. Found: C, 42.99; H, 5.97; N, 11.07. 
4-(2’-furyl)-2-(4-ethylmethoxypiperazino)pyrimidine (14, AE-001-72): This compound was ob-
tained as a yellow oil in 48 % yield (60 mg); 1H NMR: δ 8.33 (d, J = 5.0 Hz, 1H), 7.53 (s, 1H), 7.15 
(d, J = 3.4 Hz, 1H), 6.84 (d, J = 5.1 Hz, 1H), 6.51 (t, J = 1.6 Hz, 1H), 3.91 (t, J = 4.9 Hz, 4H), 3.55 (t, J 
= 5.5 Hz, 2H), 3.37 (s, 3H), 2.62 (t, J = 5.6 Hz, 2H), 2.57 (t, J = 4.9 Hz, 4H); 13C NMR: δ 160.6, 
157.3, 154.8, 151.7, 143.3, 111.1, 110.1, 102.8, 69.1, 57.9, 57.1, 52.5, 42.5; Highresolution MS 
(ESI, positive ion mode): calcd. for C15H21N4O2 (M + 1)
+, m/z 289.1658, found m/z 289.1665. A 
hydrobromide salt, mp > 250 °C.  Anal Calcd. for C15H21N4O2•2HBr: C, 40.02; H, 4.93; N, 12.45. 
Found: C, 40.01; H, 5.01; N, 12.29. 
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